Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Jan 3, 2005
Finance
Ebb & Flow
...CTCE-9908 for non-small cell lung cancer (NSCLC). The deal was underwritten by Canaccord; Jennings Capital;
McFarlane Gordon
...
Read More
BioCentury
|
Dec 30, 2004
Financial News
Chemokine prices IPO
...giving it a post-money valuation of C$29.3 million ($23.8 million). Underwriters were Canaccord; Jennings Capital;
McFarlane Gordon
...
Read More
Items per page:
10
1 - 2 of 2
BioCentury
|
Jan 3, 2005
Finance
Ebb & Flow
...CTCE-9908 for non-small cell lung cancer (NSCLC). The deal was underwritten by Canaccord; Jennings Capital;
McFarlane Gordon
...
Read More
BioCentury
|
Dec 30, 2004
Financial News
Chemokine prices IPO
...giving it a post-money valuation of C$29.3 million ($23.8 million). Underwriters were Canaccord; Jennings Capital;
McFarlane Gordon
...
Read More
Items per page:
10
1 - 2 of 2
Previous page
Next page
